Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea.

IF 3 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of Korean Medical Science Pub Date : 2024-09-30 DOI:10.3346/jkms.2024.39.e258

Young-Sook Choi, Sukhyun Ryu, Ryu Kyung Kim, Achangwa Chiara, Soojin Baek, Hojin Nam, Eunkyung Park, Eun Kyoung Kim, Young June Choe, Donghyok Kwon, Won Suk Choi

{"title":"Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea.","authors":"Young-Sook Choi, Sukhyun Ryu, Ryu Kyung Kim, Achangwa Chiara, Soojin Baek, Hojin Nam, Eunkyung Park, Eun Kyoung Kim, Young June Choe, Donghyok Kwon, Won Suk Choi","doi":"10.3346/jkms.2024.39.e258","DOIUrl":null,"url":null,"abstract":"Background: This retrospective observational matched cohort study assessed the differences in critical infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the omicron-predominant period of the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the vaccine effectiveness of bivalent mRNA vaccine compared to unvaccinated individuals.Methods: We collected COVID-19 case data from the Korean COVID-19 vaccine effectiveness cohort. We calculated the probability of critical COVID-19 cases by comparing the vaccinated and unvaccinated groups.Results: The risk of being critically infected due to SAR-CoV-2 infection was 5.96 times higher (95% confidence interval, 5.63-6.38) among older individuals who were unvaccinated compared to those who received the bivalent COVID-19 vaccine.Conclusion: Our findings indicate that the bivalent vaccine reduces the disease burden of the SARS-CoV-2 omicron variant, particularly among the older population. Further studies are warranted to determine the effectiveness of booster doses of vaccines for SARS-CoV-2 infection.","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444818/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2024.39.e258","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This retrospective observational matched cohort study assessed the differences in critical infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the omicron-predominant period of the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the vaccine effectiveness of bivalent mRNA vaccine compared to unvaccinated individuals.

Methods: We collected COVID-19 case data from the Korean COVID-19 vaccine effectiveness cohort. We calculated the probability of critical COVID-19 cases by comparing the vaccinated and unvaccinated groups.

Results: The risk of being critically infected due to SAR-CoV-2 infection was 5.96 times higher (95% confidence interval, 5.63-6.38) among older individuals who were unvaccinated compared to those who received the bivalent COVID-19 vaccine.

Conclusion: Our findings indicate that the bivalent vaccine reduces the disease burden of the SARS-CoV-2 omicron variant, particularly among the older population. Further studies are warranted to determine the effectiveness of booster doses of vaccines for SARS-CoV-2 infection.

查看原文本刊更多论文

双价 mRNA COVID-19 疫苗在大韩民国预防 SARS-CoV-2 Omicron 变体危重感染的有效性。

背景：这项回顾性观察匹配队列研究评估了2019年冠状病毒病（COVID-19）大流行期间，由严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）引起的危重感染的差异。与未接种者相比，我们评估了二价 mRNA 疫苗的接种效果：我们从韩国 COVID-19 疫苗有效性队列中收集了 COVID-19 病例数据。方法：我们从韩国 COVID-19 疫苗有效性队列中收集了 COVID-19 病例数据，通过比较接种组和未接种组，计算出 COVID-19 重症病例的概率：结果：与接种了二价 COVID-19 疫苗的人群相比，未接种疫苗的老年人因感染 SAR-CoV-2 而导致危重感染的风险是接种二价 COVID-19 疫苗人群的 5.96 倍（95% 置信区间，5.63-6.38）：我们的研究结果表明，二价疫苗可减少 SARS-CoV-2 omicron 变体的疾病负担，尤其是在老年人群中。有必要开展进一步研究，以确定加强剂量疫苗对 SARS-CoV-2 感染的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Korean Medical Science 医学-医学：内科

CiteScore

7.80

自引率

8.90%

发文量

320

审稿时长

3-6 weeks

期刊介绍： The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.